CryoPort Inc (CYRX)

[H2R]

Organic Revenue Growth of 55% (ER Q2)

Record Revenue for Second Quarter of 2021 of $56.2 million
- Revenue increased 498% year over year, with continuing strong performance by MVE Biological Solutions and CRYOPDP
- Organic Revenue Growth of 55%
- Supporting a record 561 clinical trials and eight commercial therapies in regenerative medicine


NASHVILLE, Tenn., Aug. 5, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and six-month periods ended June 30, 2021.


Jerrell Shelton, CEO of Cryoport, commented, "This was another strong quarter with excellent performance across all our business units driving both year-over-year growth and sequential growth compared with our record-breaking first quarter. Our total revenue for the quarter grew to a record $56.2 million with CRYOGENE and Cryoport Systems delivering a 55% organic growth rate year-over-year coupled with strong respective results from MVE Biological Solutions and CRYOPDP. This outstanding performance reflects the continuing successful execution of our overall growth strategy, and we expect to continue this momentum throughout the second half of 2021 and beyond as our market engagement strategies for MVE Biological Solutions and CRYOPDP are driving increasing synergies to reinforce their growth. And, of course, revenue from our eight commercial agreements and our continuously growing support of next generation and groundbreaking clinical trials continues to fuel organic growth.

"Our position as a leading life sciences supply chain partner to the regenerative medicine market has never been stronger, with Biopharma/Pharma revenue increasing 431% year over year in the second quarter of 2021 or 51% organically.

http://ir.cryoport.com/news-releases/2021/08-05-2021-211017233

Growth!